NCT00315003终止3 期
Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/kg od for 4 Days, in Children With Acute Otitis Media
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Sanofi
- 入组人数
- 1,500
- 试验地点
- 13
- 主要终点
- The primary efficacy variables will be time to symptom resolution (TSR) and clinical cure at theposttherapy/TOC Visit 3.
研究概览
简要总结
This is a multinational, randomized (1:1), double-blind, double-dummy, comparative, 2- treatmentgroup study in children (age range: ≥6 months and <72 months [< 6 years of age]) with AOM.Subjects will be randomized to receive either telithromycin (50 mg/mL) oral suspension 25 mg/kgonce daily for 5 days or azithromycin (40 mg/mL) oral suspension (10 mg/kg once on Day 1, followed by 5 mg/kg once daily on Days 2-5, not to exceed 500 mg onDay 1 and 250 mg/day from Days 2 - 5. Matching placebo suspensions for telithromycin and azithromycin will also be dispensed to provide blinding for the different treatment regimens.Assessments and reporting of safety will be carried out at all visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Months 至 6 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects meeting all of the following criteria will be considered for enrollment into the study:
- •Subjects ≥6 months and <72 months (< 6 years) of age;
- •Recent (within the last 72 hours) and rapid onset of AOM symptoms and signs;
- •The presence of MEF on otoscopy indicated by a bulging tympanic membrane;
- •Otalgia or ear tugging or touching within the last 24 hours that interferes with or precludes normal activity or sleep;
- •At least 1 of the following clinical findings not specific to AOM: fever, vomiting, diarrhea, anorexia, sleep disturbance, or irritability;
- •Caregiver-reported AOM symptoms sufficient for entry according to protocol criteria.
- •Caregiver-reported AOM symptoms diary
- •Tympanometry exhibiting:
- •Type B curve or positive pressure peak curves.
排除标准
- •Subjects presenting with any of the following will not be included in the study:
- •Uncertain diagnosis of AOM or mild to moderate symptoms and signs of AOM that would make the subject a candidate for observation and analgesic therapy with observation for 2-3 days.
- •Otorrhea or tympanostomy tube present in the ear to be evaluated;
- •Otitis externa;
- •Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis, immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency syndrome with <25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci (carinii) or requiring treatment for an opportunistic infection;
- •Known congenital long QT syndrome;
- •Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L]), hypomagnesemia, bradycardia (<50 bpm);
- •Myasthenia gravis;
- •Known impaired renal function, as shown by creatinine clearance ≤25 mL/min;
- •History of hypersensitivity or intolerance to macrolides or azithromycin;
- •Previous enrollment in this study or previous treatment with telithromycin;
- •Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol.
结局指标
主要结局
The primary efficacy variables will be time to symptom resolution (TSR) and clinical cure at theposttherapy/TOC Visit 3.
次要结局
- Adverse events (AEs) reported by subjects, their parents/legally authorized representative, orobserved by the investigators will be recorded throughout the study.
研究者
研究点 (13)
Loading locations...
相似试验
终止
3 期
TELI TAD - Telithromycin in Tonsillitis in Adolescents and AdultsTonsillitisPharyngitisNCT00315549Sanofi233
终止
3 期
TELI TON - Telithromycin in TonsillitisTonsillitisPharyngitisNCT00315042Sanofi314
已完成
3 期
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple SclerosisNCT01707992Teva Branded Pharmaceutical Products R&D, Inc.2,199
进行中（未招募）
不适用
Multinational, randomized, double-blind, double-dummy, comparative study toevaluate the efficacy and safety of telithromycin 25 mg/kg given once daily for 5 or10 days depending on age and previous treatment history versus cefuroxime axetil15 mg/kg, given twice daily for 10 days, in children with acute otitis mediaAcute otitis media in children.MedDRA version: 7Level: 2Classification code 10021881EUCTR2004-000738-34-DEAventis Pharmaceuticals, Inc.900
终止
3 期
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)NCT04157335AstraZeneca295